FCFD4514S

DRUG2 trials

Sponsors

Genentech, Inc.

Conditions

Geographic Atrophy

Phase 1

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy

CompletedNCT00973011

Genentech, Inc.Geographic Atrophy

Start: 2009-09-30End: 2010-07-31Updated: 2022-12-13

Phase 2

A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy

CompletedNCT01229215

Genentech, Inc.Geographic Atrophy

Start: 2011-02-28End: 2013-04-30Updated: 2016-11-02

Related Papers

Outer Retinal Tubulation and Geographic Atrophy: A Natural History Analysis of Sham Observed Eyes from the OAKS and DERBY Trials.

2025-05-19

Deep Learning to Predict Geographic Atrophy Area and Growth Rate from Multimodal Imaging.

2022-08-2831 citations

Reliability and Construct Validity of the NEI VFQ-25 in a Subset of Patients With Geographic Atrophy From the Phase 2 Mahalo Study.

2018-03-1042 citations

Functional Reading Independence (FRI) Index: A New Patient-Reported Outcome Measure for Patients With Geographic Atrophy.

2016-11-0135 citations

Outer retinal tubulation as a predictor of the enlargement amount of geographic atrophy in age-related macular degeneration.

2014-10-1249 citations